JP2013501807A5 - - Google Patents

Info

Publication number

JP2013501807A5

JP2013501807A5 JP2012524878A JP2012524878A JP2013501807A5 JP 2013501807 A5 JP2013501807 A5 JP 2013501807A5 JP 2012524878 A JP2012524878 A JP 2012524878A JP 2012524878 A JP2012524878 A JP 2012524878A JP 2013501807 A5 JP2013501807 A5 JP 2013501807A5

Authority

JP

Japan

Prior art keywords

seq

domain

antibody

composition

nos

Prior art date

2010-08-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 47
• 239000000427 antigen Substances 0.000 claims description 20
• 102000036639 antigens Human genes 0.000 claims description 20
• 108091007433 antigens Proteins 0.000 claims description 20
• 239000012634 fragment Substances 0.000 claims description 20
• 238000000034 method Methods 0.000 claims description 19
• 241000712461 unidentified influenza virus Species 0.000 claims description 19
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
• 101710154606 Hemagglutinin Proteins 0.000 claims description 12
• 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 12
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 12
• 101710176177 Protein A56 Proteins 0.000 claims description 12
• 239000000185 hemagglutinin Substances 0.000 claims description 12
• 239000011159 matrix material Substances 0.000 claims description 12
• 206010022000 influenza Diseases 0.000 claims description 10
• 229920001184 polypeptide Polymers 0.000 claims description 10
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
• 229940031348 multivalent vaccine Drugs 0.000 claims description 9
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
• 108090000288 Glycoproteins Proteins 0.000 claims description 8
• 102000003886 Glycoproteins Human genes 0.000 claims description 8
• 239000003112 inhibitor Substances 0.000 claims description 8
• 230000009385 viral infection Effects 0.000 claims description 8
• 239000012472 biological sample Substances 0.000 claims description 7
• 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 4
• 241000700605 Viruses Species 0.000 claims description 4
• 239000003443 antiviral agent Substances 0.000 claims description 4
• 239000013068 control sample Substances 0.000 claims description 4
• 229940126181 ion channel inhibitor Drugs 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 239000002911 sialidase inhibitor Substances 0.000 claims description 4
• 230000028993 immune response Effects 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
• 238000009007 Diagnostic Kit Methods 0.000 claims description 2
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical group C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
• 229960003805 amantadine Drugs 0.000 claims description 2
• 150000001413 amino acids Chemical group 0.000 claims description 2
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 208000037797 influenza A Diseases 0.000 claims description 2
• VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
• 229960002194 oseltamivir phosphate Drugs 0.000 claims description 2
• 229960000888 rimantadine Drugs 0.000 claims description 2
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 2
• 230000004936 stimulating effect Effects 0.000 claims description 2
• 238000011282 treatment Methods 0.000 claims description 2
• 230000003612 virological effect Effects 0.000 claims description 2
• 229960001028 zanamivir Drugs 0.000 claims description 2
• ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical group CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
• 206010022005 Influenza viral infections Diseases 0.000 claims 1
• 229960005486 vaccine Drugs 0.000 description 5
• 239000012678 infectious agent Substances 0.000 description 2
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 241001500351 Influenzavirus A Species 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1